Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000966 · ClinicalTrials.gov registry record · Phase 1
A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00000966 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 45 participants.
The verdict
NCT00000966, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
To evaluate the effectiveness and toxicity of oral azithromycin and pyrimethamine as acute therapy for toxoplasmic encephalitis in AIDS patients. To assess the toxicity and effectiveness of azithromycin alone as maintenance therapy. Encephalitis caused by Toxoplasma gondii is the most frequent cause of focal central nervous system infection in patients with AIDS. Untreated, the encephalitis is fatal. Standard treatment for toxoplasmic encephalitis is associated with serious adverse effects. Thus, alternative treatments are needed.
Interventions
- DRUG Azithromycin
- DRUG Leucovorin calcium
- DRUG Pyrimethamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000966
The ClinicalTrials.gov registry entry for NCT00000966 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azithromycin is the first listed.
NCT00000966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000966 about?
NCT00000966 is a clinical study titled "A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS". To evaluate the effectiveness and toxicity of oral azithromycin and pyrimethamine as acute therapy for toxoplasmic encephalitis in AIDS patients. To assess the toxicity and effectiveness of azithromycin alone as maintenance therapy. Encephalitis caused by Toxoplasma gondii is the most frequent caus...
What is the current status of trial NCT00000966?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants.
What interventions are being tested in trial NCT00000966?
The interventions under investigation include: Azithromycin (DRUG), Leucovorin calcium (DRUG), Pyrimethamine (DRUG).
Who is sponsoring clinical trial NCT00000966?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.